HER2 Antibody Clone: GR011 Concentrate
- Known as:
- HER2 Antibody Clone: GR011 Concentrate
- Catalog number:
- 61-0154
- Product Quantity:
- 1 mL
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- HER2 Antibody Clone: GR011 Concentrate
Related genes to: HER2 Antibody Clone: GR011 Concentrate
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 Antibody Clone: GR011 Concentrate
Related articles to: HER2 Antibody Clone: GR011 Concentrate
- To define the role of SLC7A5 expression in establishing an aggressive phenotype in primary breast cancer, specifically its correlation with major clinicopathological characteristics and the capacity for early lymphatic spread. - Source: PubMed
Kometova V VMikhaleva L MRodionov V VKireev A A - ObjectiveInavolisib, a novel highly selective PI3Kα inhibitor, is approved for treating PIK3CA-mutated, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (PIK3CA-mutated, HR+/HER2- ABC). Given its significant efficacy, as confirmed by the updated INAVO120 III trial, but also its high price, a comprehensive evaluation of its value is warranted. The purpose of this study was to investigate whether inavolisib plus palbociclib-fulvestrant is cost-effective for patients with PIK3CA-mutated, HR+/HER2- ABC from the U.S. healthcare system perspective.MethodsA Markov model comprising three health states was developed to simulate the progression of PIK3CA-mutated, HR+/HER2- ABC. Parametric survival models, fitted to and extrapolated from survival data, were used to estimate long-term clinical outcomes. Lifetime costs and health outcomes were calculated. Willingness-to-pay (WTP) thresholds were set at $100,000, $150,000, and $200,000 per quality-adjusted life year QALY to reflect general and more affluent regional standards. One-way and probabilistic sensitivity analyses were conducted to assess model robustness, and subgroup analyses explored the variation in benefits across patient clinical characteristics.ResultsCompared with placebo, inavolisib provided an additional 0.6 QALYs while increasing costs by $160,490.07, resulting in an incremental cost-effectiveness ratio (ICER) of $268,457.82 per QALY. Sensitivity analysis identified the utility of the progression-free state as the most sensitive factor in the model. Within the WTP threshold range of $100,000 to $200,000 per QALY, the inavolisib regimen was not considered cost-effective. To achieve cost-effectiveness at WTP thresholds of $100,000, $150,000, and $200,000 per QALY, the per-cycle price of inavolisib would need to be reduced to 59.5%, 72.0%, and 86.5% of its current price, respectively.ConclusionFor patients with PIK3CA-mutated HR+/HER2- ABC, the inavolisib regimen is not cost-effective in the U.S. healthcare setting. Negotiating price reductions and adjusting decision thresholds based on patient characteristics may be viable strategies to meet the extensive treatment demand in the U.S. - Source: PubMed
Publication date: 2026/04/16
Zeng HanqingSong Li-YingGuo RenDing DanZeng XiaohuiLiu Qiao - Esophagogastric junction adenocarcinomas (EGJA) pose a serious threat to health and are increasing in incidence. The Siewert classification is the recognized anatomical classification system for guiding the surgical approaches in EGJA. However, the definition of EGJA and its optimal resection strategy remain controversial. This study aims to investigate the distinct molecular relationship between EGJA subtypes and other upper gastrointestinal cancers at the molecular level. - Source: PubMed
Publication date: 2026/03/24
Qin XiaoXu LinWang XiaozhenQi YouchaoZhong WeiShang BinWang ZhouChen Gang - Dato-DXd (datopotamab deruxtecan) is an anti-TROP2 antibody-drug conjugate developed for the treatment of unresectable or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (HR+/HER2-BC) who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. Associations between Dato-DXd or its payload DXd pharmacokinetics (PK) and various efficacy and safety endpoints were investigated in the current analysis. Exposure-efficacy analysis was conducted in a total of 352 patients with HR+/HER2-BC who received Dato-DXd at 6 mg/kg every 3 weeks (Q3W). Area under the curve in cycle 1 (AUC1) was identified as a significant covariate of overall survival (OS), with higher Dato-DXd exposure associated with longer OS. Progression-free survival (PFS) showed a positive trend with higher exposure, though baseline tumor size emerged as a more significant predictor in multivariable analyses. Exposure-safety analysis revealed correlations between higher Dato-DXd or DXd PK metrics and increased risk of selected safety events, including stomatitis and ocular surface events. PopPK analysis showed that Dato-DXd exposure increased with body weight, and implementing a capped dose of 540 mg for patients ≥90 kg helped normalize exposure across weight groups. Exposure-safety analysis further supported that this approach may reduce the potential associated safety risks. These results support the recommended Dato-DXd dosing regimen (6 mg/kg Q3W with dose capping for patients ≥90 kg) and highlight its favorable benefit-risk profile in patients with HR+/HER2-breast cancer. - Source: PubMed
Tang ZoeyLim KyoungSooJiang YuDenduluri NeelimaRokutanda NanaPan YuzhuoHong YingRen SongVajjah PavanZhou Diansong - To investigate the cost-effectiveness of pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or gastro-esophageal junction adenocarcinoma from the perspective of the U.S. and Chinese healthcare systems. In this economic evaluation, a Markov model is constructed from the perspective of the U.S. and Chinese healthcare systems. The survival data were derived from the clinical trial (KEYNOTE-811), while cost data generated during treatment were sourced from pricing, databases, and expert consultations in local hospitals. Total costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) were estimated in US dollars. Its robustness is evaluated by deterministic and probabilistic sensitivity analysis. Basic case analysis showed that pembrolizumab in combination with trastuzumab and chemotherapy, as a new treatment strategy, had higher cost-effectiveness compared with trastuzumab plus chemotherapy treatment, with willingness-to-pay (WTP) thresholds set at $150,000 per QALY for the United States population and $40,334.05 per QALY for the China population The ICER was $88,507.57 per QALY in the United States and $22,461.22 per QALY in China, both below the respective thresholds. Sensitivity analysis demonstrated that the results were robust. From the perspective of the U.S. and Chinese medical and health services, pembrolizumab in combination with trastuzumab and chemotherapy is more cost-effective than chemotherapy in the treatment of HER2-positive gastric or gastro-esophageal junction adenocarcinoma patients. Within the context of China's health technology assessment and National Reimbursement Drug List negotiation framework, the ICER below the three-times-GDP threshold suggests preliminary economic feasibility at current price levels, indicating that the regimen may warrant consideration for reimbursement decisions, subject to further budget impact analysis and price negotiation. The evidence-based pricing strategies provided in this study may be helpful for decision makers and clinicians to make the best decisions in general clinical practice. More evidence on budgetary impact and patient affordability is needed. - Source: PubMed
Publication date: 2026/04/15
Yu KexinXu Qiaoping